Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia After BTK Inhibitor and/or BCL-2 Inhibitor Failure. (2024). Canadian Hematology Today, 3(2), 49–53. https://doi.org/10.58931/cht.2024.3255